Partnership Solutions
Scale Up with FLOWSMART
SP²TX’s FLOWSMART platform empowers pharmaceutical companies to revolutionize their peptide API production through next-generation flow chemistry. Our technology enables partners to achieve unprecedented efficiency and scale in peptide manufacturing.
Customizable Licensing Options
- Flexible licensing options to support your business at every stage
- Synthesis-as-a-Service subscription model available
- Optional region and product market exclusivity add-ons
Technology Integration
- Modular system design enables seamless installation in existing GMP facilities
- Comprehensive validation and analytical support from a world-class scientific team with expertise in solid phase peptide synthesis
- Process optimization protocols to maximize FLOWSMART yield performance
Asset Licensing & Co-Development
- License early-stage assets from SP2TX’s peptide therapeutic pipeline*
- Co-develop novel peptide APIs with shared costs and development risk
- Access SP2TX’s peptide design and synthesis expertise
*Current pipeline includes obesity, muscle-preservation, and antimicrobial peptides
Our Benchmark: Commercial Generic API’s
| Single Batch Capacity | Crude Yield | Final Yield* | Time to Synthesize | |
|---|---|---|---|---|
| Semaglutide¹ | 100g | 99% | 55% | 12 hrs |
| Tirzapatide¹ | 100g | 99% | 60% | 14 hrs |
| Synthetic EGF’s | 100g | 60% | 25% | 16 hrs |
*Final purity ≥ 99%
¹Research use exemption to patent infringement
Performance Metrics for Tirzepatide
Demonstrated advantages over traditional methods:
2.7x lower production costs*
2.5x higher yields†
7-14x faster synthesis
85% reduced solvent consumption‡
*Based on 200kg annual production comparison
†45% vs 18% for traditional methods
‡Through solvent recycling and EA recovery
Company
Contact
Institute of Molecular Biology & Genetics, Bldg 105, Rm 312, Seoul National University, Gwanak-ro 1, Gwanak-gu, Seoul, Korea 151-742